AstraZeneca plc Given Buy Rating at Liberum Capital (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reiterated by Liberum Capital in a research note issued on Wednesday. They currently have a GBX 5,800 ($99.49) target price on the stock. Liberum Capital’s price target would indicate a potential upside of 32.98% from the stock’s previous close.
Shares of AstraZeneca plc (LON:AZN) traded down 0.01% during mid-day trading on Wednesday, hitting GBX 4361.50. The stock had a trading volume of 1,095,976 shares. AstraZeneca plc has a 52 week low of GBX 3086.50 and a 52 week high of GBX 5750.00. The stock’s 50-day moving average is GBX 4357.27 and its 200-day moving average is GBX 4082.. The company’s market cap is £54.999 billion.
AZN has been the subject of a number of other recent research reports. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Friday, July 4th. They now have a GBX 4,900 ($84.05) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “underweight” rating on shares of AstraZeneca plc in a research note on Thursday, July 3rd. They now have a GBX 3,700 ($63.46) price target on the stock. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, July 2nd. They now have a GBX 3,950 ($67.75) price target on the stock. Seven investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of GBX 4,065.87 ($69.74).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.